Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. Shares of Exact ...
Business Insider4d
Exact Sciences price target lowered to $70 from $75 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a ...
Exact Sciences: Long-Term Growth Prospects Intact Despite Short-Term Challenges
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Zacks.com on MSN4d
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in ...
CNN1y
Exact Sciences Corporation
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...
Yahoo Finance5d
Exact Sciences Announces Third-Quarter 2024 Results
November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 ...
pharmaphorum4y
Exact Sciences buys cancer detection company Thrive for $2.15 billion
Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and ...
MarketWatch5d
Exact Sciences Stock Falls After Cutting Outlook, Posting Lower-Than-Expected 3Q Results
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
Benzinga.com1mon
Exact Sciences (NASDAQ:EXAS) Stock Quotes, Forecast and News Summary
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average ...
Yahoo Finance5d
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight
Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.
Yahoo Finance4d
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...